U.S. Markets close in 4 hrs 35 mins
  • S&P 500

    4,164.54
    +1.25 (+0.03%)
     
  • Dow 30

    34,259.62
    -68.17 (-0.20%)
     
  • Nasdaq

    13,472.87
    +93.82 (+0.70%)
     
  • Russell 2000

    2,238.73
    +11.61 (+0.52%)
     
  • Crude Oil

    65.97
    -0.30 (-0.45%)
     
  • Gold

    1,868.00
    +0.40 (+0.02%)
     
  • Silver

    28.32
    +0.04 (+0.15%)
     
  • EUR/USD

    1.2209
    +0.0052 (+0.4273%)
     
  • 10-Yr Bond

    1.6450
    +0.0050 (+0.30%)
     
  • Vix

    19.47
    -0.25 (-1.27%)
     
  • GBP/USD

    1.4194
    +0.0057 (+0.4031%)
     
  • USD/JPY

    108.9370
    -0.2630 (-0.2408%)
     
  • BTC-USD

    43,532.67
    -418.80 (-0.95%)
     
  • CMC Crypto 200

    1,212.57
    -40.58 (-3.24%)
     
  • FTSE 100

    7,038.68
    +5.83 (+0.08%)
     
  • Nikkei 225

    28,406.84
    +582.01 (+2.09%)
     

BioMarin's Hemophilia Gene Therapy Scores RMAT Designation In US

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BioMarin Pharmaceutical Inc's (NASDAQ: BMRN) valoctocogene roxaparvovec investigational gene therapy for the treatment of adults with severe hemophilia A. 

  • RMAT is an expedited program intended to facilitate the development and review of regenerative medicine therapies.

  • In January, Phase 3 data were reported from patients with five bleeding episodes per year and using about 136-factor infusions per year.

  • Gene therapy treatment cut those average annualized numbers by 84% and 99%, respectively, to just under one and two.

  • In August last year, the Company received FDA Complete Response Letter for valoctocogene roxaparvovec.

  • The agency recommended that the Company complete the Phase 3 GENEr8-1 study and submit two-year follow-up safety and efficacy data.

  • In the EU, BioMarin is targeting submission of the marketing application with these results to the EMA in the second quarter of 2021, pending confirmation in planned pre-submission meetings.

  • Price Action: BMRN shares gained 0.66% at $78.22 in market trading hours on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.